NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis

被引:52
|
作者
Fattorusso, R
Pellecchia, M
Viti, F
Neri, P
Neri, D
Wüthrich, K
机构
[1] ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland
[2] Univ Siena, Dipartimento Biol Mol, Sez Biochim, I-53100 Siena, Italy
关键词
angiogenesis marker; ED-B domain; fibronectin isoform; NMR;
D O I
10.1016/S0969-2126(99)80051-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The process of angiogenesis (i.e. the formation of new blood vessels from pre-existing ones) is fundamental to physiological processes such as reproduction, development and repair, as well;Is to pathological conditions such as tumor progression, rheumathoid arthritis and ocular disorders. The oncofoetal ED-B domain, a specific marker of angiogenesis, consists of 91 amino acid residues that are inserted by alternative splicing into the fibronectin (FN) molecule. Results: The NMR structure of the ED-B domain is reported and reveals important differences from other FN type III domains. A comparison of the ED-B domain with the crystal structure of a four-domain FN fragment shows the novel features of ED-B to be located in loop regions that are buried at interdomain interfaces, and which therefore largely determine the global shape of the FN molecule. The negatively charged amino acids in this highly acidic protein are uniformly distributed over the molecular surface, with the sole exception of a solvent-exposed hydrophobic patch that represents a potential specific recognition site. Epitope mapping with 82 decapeptides that span the ED-B sequence revealed that three ED-B-specific monoclonal antibodies, which selectively target newly forming blood vessels in tumor-bearing mice, bind to adjacent regions on the ED-B surface. Conclusions: The NMR structure enables the identification of a large surface area of the ED-B domain that appears to be accessible in vivo, opening up new diagnostic and therapeutic opportunities. Furthermore, the mapping of specific monoclonal antibodies to the three-dimensional structure of the ED-B domain, and their use in angiogenesis inhibition experiments, provides a basis for further investigation of the role of the ED-B domain in the formation of new blood vessels.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [41] Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn’s disease (CD) mucosa
    Julia Brenmoehl
    Markus Lang
    Martin Hausmann
    Sandra N. Leeb
    Werner Falk
    Jürgen Schölmerich
    Michael Göke
    Gerhard Rogler
    International Journal of Colorectal Disease, 2007, 22 : 611 - 623
  • [42] Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa
    Brenmoehl, Julia
    Lang, Markus
    Hausmann, Martin
    Leeb, Sandra N.
    Falk, Werner
    Schoelmerich, Juergen
    Goeke, Michael
    Rogler, Gerhard
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2007, 22 (06) : 611 - 623
  • [43] INSULIN-LIKE GROWTH-FACTOR-I ENHANCES THE PRESENCE OF A SPLICED ISOFORM OF FIBRONECTIN (ED-B FIBRONECTIN) IN NORMAL AND OSTEOARTHRITIC HUMAN CARTILAGES
    CHEVALIER, X
    CLAUDEPIERRE, P
    GROULT, N
    ZARDI, L
    LARGETPIET, B
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 38 - 38
  • [44] Discovery and investigation of lead compounds as binders to the extra-domain B of the angiogenesis marker, fibronectin
    Scheuermann, J
    Volonterio, A
    Zerbe, O
    Zanda, M
    Neri, D
    DRUG DEVELOPMENT RESEARCH, 2003, 58 (03) : 268 - 282
  • [45] Targeting of ED-B fibronectin for tumor imaging using a 99mTc labeled human recombinant antibody fragment.
    Berndorff, D
    Moosmayer, D
    Hilger, CS
    Dinkelborg, L
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 153P - 153P
  • [46] Oncofoetal fibronectin - a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma
    Hesse, E
    Musholt, PB
    Potter, E
    Petrich, T
    Wehmeier, M
    von Wasielewski, R
    Lichtinghagen, R
    Musholt, TJ
    BRITISH JOURNAL OF CANCER, 2005, 93 (05) : 565 - 570
  • [47] Oncofoetal fibronectin – a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma
    E Hesse
    P B Musholt
    E Potter
    T Petrich
    M Wehmeier
    R von Wasielewski
    R Lichtinghagen
    T J Musholt
    British Journal of Cancer, 2005, 93 : 565 - 570
  • [48] MYOFIBROBLAST AND CONCURRENT ED-B FIBRONECTIN PHENOTYPE IN HUMAN STROMAL CELLS CULTURED FROM NONMALIGNANT AND MALIGNANT BREAST-TISSUE
    BROUTYBOYE, D
    MAGNIEN, V
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (01) : 66 - 73
  • [49] COORDINATE ONCODEVELOPMENTAL MODULATION OF ALTERNATIVE SPLICING OF FIBRONECTIN PREMESSENGER RNA AT ED-A, ED-B, AND CS1 REGIONS IN HUMAN LIVER-TUMORS
    OYAMA, F
    HIROHASHI, S
    SAKAMOTO, M
    TITANI, K
    SEKIGUCHI, K
    CANCER RESEARCH, 1993, 53 (09) : 2005 - 2011
  • [50] Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population
    Claudepierre, P
    Allanore, Y
    Belec, L
    Larget-Piet, B
    Zardi, L
    Chevalier, X
    RHEUMATOLOGY, 1999, 38 (11) : 1099 - 1103